R
144.83
13.16 (9.99%)
| Penutupan Terdahulu | 131.67 |
| Buka | 146.22 |
| Jumlah Dagangan | 5,447,914 |
| Purata Dagangan (3B) | 2,856,739 |
| Modal Pasaran | 30,789,781,504 |
| Harga / Jualan (P/S) | 9.04 |
| Harga / Buku (P/B) | 18.32 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 May 2026 |
| EPS Cair (TTM) | -4.01 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 6.46% |
| Nisbah Semasa (MRQ) | 13.46 |
| Aliran Tunai Operasi (OCF TTM) | -591.31 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -349.13 M |
| Pulangan Atas Aset (ROA TTM) | -23.09% |
| Pulangan Atas Ekuiti (ROE TTM) | -36.68% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Revolution Medicines, Inc. | Menaik | Menaik |
AISkor Stockmoo
-0.1
| Konsensus Penganalisis | -1.5 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 4.0 |
| Purata | -0.10 |
|
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 2.02% |
| % Dimiliki oleh Institusi | 105.87% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Bellevue Group Ag | 31 Dec 2025 | 5,005,719 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 145.00 (Needham, 0.12%) | Beli |
| Median | 133.00 (-8.17%) | |
| Rendah | 120.00 (Piper Sandler, -17.14%) | Beli |
| Purata | 132.75 (-8.34%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 100.90 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Needham | 26 Feb 2026 | 145.00 (0.12%) | Beli | 102.15 |
| Piper Sandler | 26 Feb 2026 | 120.00 (-17.14%) | Beli | 102.15 |
| Wells Fargo | 26 Feb 2026 | 144.00 (-0.57%) | Beli | 102.15 |
| JP Morgan | 02 Feb 2026 | 122.00 (-15.76%) | Beli | 97.16 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 13 Apr 2026 | CNBC | Revolution Medicines says its potential breakthrough pancreatic cancer drug succeeds in late-stage trial |
| 04 Feb 2026 | Pengumuman | Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |